Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35038433

Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2022 Feb
First author
Safran HP

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Feb;23(2):188-190. doi: 10.1016/S1470-2045(22)00004-3.
    note
    Source null
    related pmid
    35038428
    relationship
    Comment in

Authors and identifiers

  1. name
    Safran HP
    type
    Author
  2. name
    Winter K
    type
    Author
  3. name
    Ilson DH
    type
    Author
  4. name
    Wigle D
    type
    Author
  5. name
    DiPetrillo T
    type
    Author
  6. name
    Haddock MG
    type
    Author
  7. name
    Hong TS
    type
    Author
  8. name
    Leichman LP
    type
    Author
  9. name
    Rajdev L
    type
    Author
  10. name
    Resnick M
    type
    Author
  11. name
    Kachnic LA
    type
    Author
  12. name
    Seaward S
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Safran HP
    type
    Author
  2. name
    Winter K
    type
    Author
  3. name
    Ilson DH
    type
    Author
  4. name
    Wigle D
    type
    Author
  5. name
    DiPetrillo T
    type
    Author
  6. name
    Haddock MG
    type
    Author
  7. name
    Hong TS
    type
    Author
  8. name
    Leichman LP
    type
    Author
  9. name
    Rajdev L
    type
    Author
  10. name
    Resnick M
    type
    Author
  11. name
    Kachnic LA
    type
    Author
  12. name
    Seaward S
    type
    Author
bibliography ids
  1. nci-bib-24c3f6f90268fc4c002f142f
book metadata
content sha256
5f06571aa9e6a7e12143229fdaa16adce674009881d2d8313bd01de6c45a3d84
document type
citation
dois
  1. 10.1016/S1470-2045(21)00718-X
electronic publication date
display
2022 Jan 14
precision
day
year
2022
evidence scope
bibliographic_metadata_only
id
pubmed:35038433
immutable id
pubmed:35038433@5f06571aa9e6a7e12143229fdaa16adce674009881d2d8313bd01de6c45a3d84
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
2
name
The Lancet. Oncology
nlm unique id
100957246
pages
259-269
volume
23
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Feb;23(2):188-190. doi: 10.1016/S1470-2045(22)00004-3.
    note
    Source null
    related pmid
    35038428
    relationship
    Comment in
outcomes validated
false
pmid
35038433
provenance
batch id
3f4d1914d2afe41e9e70
provider
NCBI PubMed ESummary
record sha256
9bdd8374bf21ca4e2a56e1a4422fd009e1a93051012f41c326151d002097b41a
response sha256
0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
retrieved at
2026-09-09T23:48:06.522634+00:00
publication date
display
2022 Feb
precision
month
year
2022
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35038433/
title
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial.

Preserved source evidence · Not medical advice